Skip to main content
Top
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Research

Identification of metabolites with anticancer properties by computational metabolomics

Authors: Adrian K Arakaki, Roman Mezencev, Nathan J Bowen, Ying Huang, John F McDonald, Jeffrey Skolnick

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Abstract

Background

Certain endogenous metabolites can influence the rate of cancer cell growth. For example, diacylglycerol, ceramides and sphingosine, NAD+ and arginine exert this effect by acting as signaling molecules, while carrying out other important cellular functions. Metabolites can also be involved in the control of cell proliferation by directly regulating gene expression in ways that are signaling pathway-independent, e.g. by direct activation of transcription factors or by inducing epigenetic processes. The fact that metabolites can affect the cancer process on so many levels suggests that the change in concentration of some metabolites that occurs in cancer cells could have an active role in the progress of the disease.

Results

CoMet, a fully automated Computational Metabolomics method to predict changes in metabolite levels in cancer cells compared to normal references has been developed and applied to Jurkat T leukemia cells with the goal of testing the following hypothesis: Up or down regulation in cancer cells of the expression of genes encoding for metabolic enzymes leads to changes in intracellular metabolite concentrations that contribute to disease progression. All nine metabolites predicted to be lowered in Jurkat cells with respect to lymphoblasts that were examined (riboflavin, tryptamine, 3-sulfino-L-alanine, menaquinone, dehydroepiandrosterone, α-hydroxystearic acid, hydroxyacetone, seleno-L-methionine and 5,6-dimethylbenzimidazole), exhibited antiproliferative activity that has not been reported before, while only two (bilirubin and androsterone) of the eleven tested metabolites predicted to be increased or unchanged in Jurkat cells displayed significant antiproliferative activity.

Conclusion

These results: a) demonstrate that CoMet is a valuable method to identify potential compounds for experimental validation, b) indicate that cancer cell metabolism may be regulated to reduce the intracellular concentration of certain antiproliferative metabolites, leading to uninhibited cellular growth and c) suggest that many other endogenous metabolites with important roles in carcinogenesis are awaiting discovery.
Appendix
Available only for authorised users
Literature
1.
go back to reference Warburg O, Posener K, Negelein E: Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift. 1924, 152: 319-344. Warburg O, Posener K, Negelein E: Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift. 1924, 152: 319-344.
2.
go back to reference Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer cell. 2007, 11 (1): 37-51. 10.1016/j.ccr.2006.10.020CrossRefPubMed Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer cell. 2007, 11 (1): 37-51. 10.1016/j.ccr.2006.10.020CrossRefPubMed
3.
go back to reference Araujo EP, Carvalheira JB, Velloso LA: Disruption of metabolic pathways--perspectives for the treatment of cancer. Current cancer drug targets. 2006, 6 (1): 77-87. 10.2174/156800906775471734CrossRefPubMed Araujo EP, Carvalheira JB, Velloso LA: Disruption of metabolic pathways--perspectives for the treatment of cancer. Current cancer drug targets. 2006, 6 (1): 77-87. 10.2174/156800906775471734CrossRefPubMed
4.
go back to reference Griner EM, Kazanietz MG: Protein kinase C and other diacylglycerol effectors in cancer. Nature reviews. 2007, 7 (4): 281-294. 10.1038/nrc2110PubMed Griner EM, Kazanietz MG: Protein kinase C and other diacylglycerol effectors in cancer. Nature reviews. 2007, 7 (4): 281-294. 10.1038/nrc2110PubMed
5.
go back to reference Ogretmen B: Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS letters. 2006, 580 (23): 5467-5476. 10.1016/j.febslet.2006.08.052CrossRefPubMed Ogretmen B: Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS letters. 2006, 580 (23): 5467-5476. 10.1016/j.febslet.2006.08.052CrossRefPubMed
6.
go back to reference Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. The Biochemical journal. 2007, 402 (2): 205-218. 10.1042/BJ20061638PubMedCentralCrossRefPubMed Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. The Biochemical journal. 2007, 402 (2): 205-218. 10.1042/BJ20061638PubMedCentralCrossRefPubMed
7.
go back to reference Yang T, Sauve AA: NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. The AAPS journal. 2006, 8 (4): E632-43. 10.1208/aapsj080472PubMedCentralCrossRefPubMed Yang T, Sauve AA: NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. The AAPS journal. 2006, 8 (4): E632-43. 10.1208/aapsj080472PubMedCentralCrossRefPubMed
8.
go back to reference Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, Shiels PG: Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006, 95 (8): 1056-1061. 10.1038/sj.bjc.6603384PubMedCentralCrossRefPubMed Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, Shiels PG: Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006, 95 (8): 1056-1061. 10.1038/sj.bjc.6603384PubMedCentralCrossRefPubMed
9.
go back to reference Grabon W: [Arginine as a crucial amino acid in carcinogenesis and tumor growth]. Postepy higieny i medycyny doswiadczalnej (Online). 2006, 60: 483-489. Grabon W: [Arginine as a crucial amino acid in carcinogenesis and tumor growth]. Postepy higieny i medycyny doswiadczalnej (Online). 2006, 60: 483-489.
10.
go back to reference Ladurner AG: Rheostat control of gene expression by metabolites. Molecular cell. 2006, 24 (1): 1-11. 10.1016/j.molcel.2006.09.002CrossRefPubMed Ladurner AG: Rheostat control of gene expression by metabolites. Molecular cell. 2006, 24 (1): 1-11. 10.1016/j.molcel.2006.09.002CrossRefPubMed
11.
go back to reference Sashital DG, Butcher SE: Flipping off the riboswitch: RNA structures that control gene expression. ACS chemical biology. 2006, 1 (6): 341-345. 10.1021/cb6002465CrossRefPubMed Sashital DG, Butcher SE: Flipping off the riboswitch: RNA structures that control gene expression. ACS chemical biology. 2006, 1 (6): 341-345. 10.1021/cb6002465CrossRefPubMed
12.
go back to reference Sommer S, Fuqua SA: Estrogen receptor and breast cancer. Seminars in cancer biology. 2001, 11 (5): 339-352. 10.1006/scbi.2001.0389CrossRefPubMed Sommer S, Fuqua SA: Estrogen receptor and breast cancer. Seminars in cancer biology. 2001, 11 (5): 339-352. 10.1006/scbi.2001.0389CrossRefPubMed
14.
go back to reference Takahashi H, McCaffery JM, Irizarry RA, Boeke JD: Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Molecular cell. 2006, 23 (2): 207-217. 10.1016/j.molcel.2006.05.040CrossRefPubMed Takahashi H, McCaffery JM, Irizarry RA, Boeke JD: Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Molecular cell. 2006, 23 (2): 207-217. 10.1016/j.molcel.2006.05.040CrossRefPubMed
15.
go back to reference Chiang KP, Niessen S, Saghatelian A, Cravatt BF: An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chemistry & biology. 2006, 13 (10): 1041-1050. 10.1016/j.chembiol.2006.08.008CrossRef Chiang KP, Niessen S, Saghatelian A, Cravatt BF: An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chemistry & biology. 2006, 13 (10): 1041-1050. 10.1016/j.chembiol.2006.08.008CrossRef
16.
go back to reference Zamanakou M, Germenis AE, Karanikas V: Tumor immune escape mediated by indoleamine 2, 3-dioxygenase. Immunol Lett. 2007, 111 (2): 69-75. 2007/07/24, 10.1016/j.imlet.2007.06.001CrossRefPubMed Zamanakou M, Germenis AE, Karanikas V: Tumor immune escape mediated by indoleamine 2, 3-dioxygenase. Immunol Lett. 2007, 111 (2): 69-75. 2007/07/24, 10.1016/j.imlet.2007.06.001CrossRefPubMed
17.
go back to reference Narta UK, Kanwar SS, Azmi W: Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Critical reviews in oncology/hematology. 2007, 61 (3): 208-221. 10.1016/j.critrevonc.2006.07.009CrossRefPubMed Narta UK, Kanwar SS, Azmi W: Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Critical reviews in oncology/hematology. 2007, 61 (3): 208-221. 10.1016/j.critrevonc.2006.07.009CrossRefPubMed
18.
go back to reference Ippolito JE, Merritt ME, Backhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI: Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103 (33): 12505-12510. 10.1073/pnas.0605207103PubMedCentralCrossRefPubMed Ippolito JE, Merritt ME, Backhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI: Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103 (33): 12505-12510. 10.1073/pnas.0605207103PubMedCentralCrossRefPubMed
19.
go back to reference Reynolds G, Wilson M, Peet A, Arvanitis TN: An algorithm for the automated quantitation of metabolites in in vitro NMR signals. Magn Reson Med. 2006, 56 (6): 1211-1219. 10.1002/mrm.21081CrossRefPubMed Reynolds G, Wilson M, Peet A, Arvanitis TN: An algorithm for the automated quantitation of metabolites in in vitro NMR signals. Magn Reson Med. 2006, 56 (6): 1211-1219. 10.1002/mrm.21081CrossRefPubMed
20.
go back to reference Want EJ, Cravatt BF, Siuzdak G: The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem. 2005, 6 (11): 1941-1951. 10.1002/cbic.200500151CrossRefPubMed Want EJ, Cravatt BF, Siuzdak G: The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem. 2005, 6 (11): 1941-1951. 10.1002/cbic.200500151CrossRefPubMed
21.
go back to reference Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977, 19 (5): 621-626. 10.1002/ijc.2910190505CrossRefPubMed Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977, 19 (5): 621-626. 10.1002/ijc.2910190505CrossRefPubMed
22.
go back to reference Cohen JD, Robins HI, Katz TB, Miller EM, Kuzminsky SR, Javid MJ: Deoxyribonucleoside triphosphate pools and thymidine chemosensitization in human T-cell leukemia. Leukemia research. 1993, 17 (2): 167-174. 10.1016/0145-2126(93)90062-PCrossRefPubMed Cohen JD, Robins HI, Katz TB, Miller EM, Kuzminsky SR, Javid MJ: Deoxyribonucleoside triphosphate pools and thymidine chemosensitization in human T-cell leukemia. Leukemia research. 1993, 17 (2): 167-174. 10.1016/0145-2126(93)90062-PCrossRefPubMed
23.
go back to reference Harris SG, Phipps RP: Prostaglandin D-2, its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology. 2002, 105 (1): 23-34. 10.1046/j.0019-2805.2001.01340.xPubMedCentralCrossRefPubMed Harris SG, Phipps RP: Prostaglandin D-2, its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology. 2002, 105 (1): 23-34. 10.1046/j.0019-2805.2001.01340.xPubMedCentralCrossRefPubMed
24.
go back to reference Gao N, Rahmani M, Dent P, Grant S: 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene. 2005, 24 (23): 3797-3809. 10.1038/sj.onc.1208530PubMedCentralCrossRefPubMed Gao N, Rahmani M, Dent P, Grant S: 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene. 2005, 24 (23): 3797-3809. 10.1038/sj.onc.1208530PubMedCentralCrossRefPubMed
25.
go back to reference Blagosklonny MV, Neckers LM: Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. Cancer letters. 1994, 76 (2-3): 81-86. 10.1016/0304-3835(94)90381-6CrossRefPubMed Blagosklonny MV, Neckers LM: Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. Cancer letters. 1994, 76 (2-3): 81-86. 10.1016/0304-3835(94)90381-6CrossRefPubMed
26.
go back to reference Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan S: Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006, 20 (1): 73-79. 10.1111/j.1472-8206.2005.00389.xCrossRefPubMed Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan S: Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006, 20 (1): 73-79. 10.1111/j.1472-8206.2005.00389.xCrossRefPubMed
27.
go back to reference Kniep B, Kniep E, Ozkucur N, Barz S, Bachmann M, Malisan F, Testi R, Rieber EP: 9-O-acetyl GD3 protects tumor cells from apoptosis. Int J Cancer. 2006, 119 (1): 67-73. 10.1002/ijc.21788CrossRefPubMed Kniep B, Kniep E, Ozkucur N, Barz S, Bachmann M, Malisan F, Testi R, Rieber EP: 9-O-acetyl GD3 protects tumor cells from apoptosis. Int J Cancer. 2006, 119 (1): 67-73. 10.1002/ijc.21788CrossRefPubMed
28.
go back to reference Batiuk TD, Schnizlein-Bick C, Plotkin Z, Dagher PC: Guanine nucleosides and Jurkat cell death: roles of ATP depletion and accumulation of deoxyribonucleotides. American journal of physiology. 2001, 281 (6): C1776-84.PubMed Batiuk TD, Schnizlein-Bick C, Plotkin Z, Dagher PC: Guanine nucleosides and Jurkat cell death: roles of ATP depletion and accumulation of deoxyribonucleotides. American journal of physiology. 2001, 281 (6): C1776-84.PubMed
29.
go back to reference Gelfand EW, Lee JJ, Dosch HM: Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proceedings of the National Academy of Sciences of the United States of America. 1979, 76 (4): 1998-2002. 10.1073/pnas.76.4.1998PubMedCentralCrossRefPubMed Gelfand EW, Lee JJ, Dosch HM: Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proceedings of the National Academy of Sciences of the United States of America. 1979, 76 (4): 1998-2002. 10.1073/pnas.76.4.1998PubMedCentralCrossRefPubMed
30.
go back to reference Saldeen J, Tillmar L, Karlsson E, Welsh N: Nicotinamide- and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003, 243 (1-2): 113-122. 10.1023/A:1021651811345CrossRefPubMed Saldeen J, Tillmar L, Karlsson E, Welsh N: Nicotinamide- and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003, 243 (1-2): 113-122. 10.1023/A:1021651811345CrossRefPubMed
31.
go back to reference Du J, Suzuki H, Nagase F, Akhand AA, Yokoyama T, Miyata T, Kurokawa K, Nakashima I: Methylglyoxal induces apoptosis in Jurkat leukemia T cells by activating c-Jun N-terminal kinase. Journal of cellular biochemistry. 2000, 77 (2): 333-344. 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-QCrossRefPubMed Du J, Suzuki H, Nagase F, Akhand AA, Yokoyama T, Miyata T, Kurokawa K, Nakashima I: Methylglyoxal induces apoptosis in Jurkat leukemia T cells by activating c-Jun N-terminal kinase. Journal of cellular biochemistry. 2000, 77 (2): 333-344. 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-QCrossRefPubMed
32.
go back to reference Fernanda Cury-Boaventura M, Cristine Kanunfre C, Gorjao R, Martins de Lima T, Curi R: Mechanisms involved in Jurkat cell death induced by oleic and linoleic acids. Clinical nutrition (Edinburgh, Scotland). 2006, 25 (6): 1004-1014.CrossRef Fernanda Cury-Boaventura M, Cristine Kanunfre C, Gorjao R, Martins de Lima T, Curi R: Mechanisms involved in Jurkat cell death induced by oleic and linoleic acids. Clinical nutrition (Edinburgh, Scotland). 2006, 25 (6): 1004-1014.CrossRef
33.
go back to reference Wacholtz MC, Minakuchi R, Lipsky PE: Characterization of the 3', 5'-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cellular immunology. 1991, 135 (2): 285-298. 10.1016/0008-8749(91)90274-FCrossRefPubMed Wacholtz MC, Minakuchi R, Lipsky PE: Characterization of the 3', 5'-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cellular immunology. 1991, 135 (2): 285-298. 10.1016/0008-8749(91)90274-FCrossRefPubMed
34.
go back to reference Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L: HMDB: the Human Metabolome Database. Nucleic acids research. 2007, 35 (Database issue): D521-6. 10.1093/nar/gkl923PubMedCentralCrossRefPubMed Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L: HMDB: the Human Metabolome Database. Nucleic acids research. 2007, 35 (Database issue): D521-6. 10.1093/nar/gkl923PubMedCentralCrossRefPubMed
35.
go back to reference Hensold JO, Barth D, Stratton CA: RNA polymerase II inhibitor, 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) causes erythroleukemic differentiation and transcriptional activation of erythroid genes. Journal of cellular physiology. 1996, 168 (1): 105-113. 10.1002/(SICI)1097-4652(199607)168:1<105::AID-JCP13>3.0.CO;2-6CrossRefPubMed Hensold JO, Barth D, Stratton CA: RNA polymerase II inhibitor, 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) causes erythroleukemic differentiation and transcriptional activation of erythroid genes. Journal of cellular physiology. 1996, 168 (1): 105-113. 10.1002/(SICI)1097-4652(199607)168:1<105::AID-JCP13>3.0.CO;2-6CrossRefPubMed
36.
go back to reference Paley EL: Tryptamine-mediated stabilization of tryptophanyl-tRNA synthetase in human cervical carcinoma cell line. Cancer letters. 1999, 137 (1): 1-7. 10.1016/S0304-3835(98)00342-5CrossRefPubMed Paley EL: Tryptamine-mediated stabilization of tryptophanyl-tRNA synthetase in human cervical carcinoma cell line. Cancer letters. 1999, 137 (1): 1-7. 10.1016/S0304-3835(98)00342-5CrossRefPubMed
37.
go back to reference Calonghi N, Cappadone C, Pagnotta E, Farruggia G, Buontempo F, Boga C, Brusa GL, Santucci MA, Masotti L: 9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cells. Biochem Biophys Res Commun. 2004, 314 (1): 138-142. 10.1016/j.bbrc.2003.12.066CrossRefPubMed Calonghi N, Cappadone C, Pagnotta E, Farruggia G, Buontempo F, Boga C, Brusa GL, Santucci MA, Masotti L: 9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cells. Biochem Biophys Res Commun. 2004, 314 (1): 138-142. 10.1016/j.bbrc.2003.12.066CrossRefPubMed
38.
go back to reference Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anti-cancer drugs. 2006, 17 (5): 521-526. 10.1097/00001813-200606000-00005CrossRefPubMed Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anti-cancer drugs. 2006, 17 (5): 521-526. 10.1097/00001813-200606000-00005CrossRefPubMed
39.
go back to reference Calonghi N, Cappadone C, Pagnotta E, Boga C, Bertucci C, Fiori J, Tasco G, Casadio R, Masotti L: Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J Lipid Res. 2005, 46 (8): 1596-1603. 10.1194/jlr.M400424-JLR200CrossRefPubMed Calonghi N, Cappadone C, Pagnotta E, Boga C, Bertucci C, Fiori J, Tasco G, Casadio R, Masotti L: Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J Lipid Res. 2005, 46 (8): 1596-1603. 10.1194/jlr.M400424-JLR200CrossRefPubMed
40.
go back to reference Calonghi N, Pagnotta E, Parolin C, Tognoli C, Boga C, Masotti L: 9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. Biochem Biophys Res Commun. 2006, 342 (2): 585-588. 10.1016/j.bbrc.2006.02.008CrossRefPubMed Calonghi N, Pagnotta E, Parolin C, Tognoli C, Boga C, Masotti L: 9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. Biochem Biophys Res Commun. 2006, 342 (2): 585-588. 10.1016/j.bbrc.2006.02.008CrossRefPubMed
41.
go back to reference Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, Yuo A, Ohyashiki K: Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia. 2001, 15 (7): 1111-1117. 10.1038/sj.leu.2402155CrossRefPubMed Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, Yuo A, Ohyashiki K: Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia. 2001, 15 (7): 1111-1117. 10.1038/sj.leu.2402155CrossRefPubMed
42.
go back to reference Stalteri MA, Harrison AP: Interpretation of multiple probe sets mapping to the same gene in Affymetrix GeneChips. BMC Bioinformatics. 2007, 8: 13- 10.1186/1471-2105-8-13PubMedCentralCrossRefPubMed Stalteri MA, Harrison AP: Interpretation of multiple probe sets mapping to the same gene in Affymetrix GeneChips. BMC Bioinformatics. 2007, 8: 13- 10.1186/1471-2105-8-13PubMedCentralCrossRefPubMed
43.
go back to reference Zakharkin SO, Kim K, Mehta T, Chen L, Barnes S, Scheirer KE, Parrish RS, Allison DB, Page GP: Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics. 2005, 6: 214- 10.1186/1471-2105-6-214PubMedCentralCrossRefPubMed Zakharkin SO, Kim K, Mehta T, Chen L, Barnes S, Scheirer KE, Parrish RS, Allison DB, Page GP: Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics. 2005, 6: 214- 10.1186/1471-2105-6-214PubMedCentralCrossRefPubMed
44.
go back to reference Lee JM, Gianchandani EP, Papin JA: Flux balance analysis in the era of metabolomics. Brief Bioinform. 2006, 7 (2): 140-150. 10.1093/bib/bbl007CrossRefPubMed Lee JM, Gianchandani EP, Papin JA: Flux balance analysis in the era of metabolomics. Brief Bioinform. 2006, 7 (2): 140-150. 10.1093/bib/bbl007CrossRefPubMed
45.
go back to reference Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM: Single-gene disorders: what role could moonlighting enzymes play?. American journal of human genetics. 2005, 76 (6): 911-924. 10.1086/430799PubMedCentralCrossRefPubMed Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM: Single-gene disorders: what role could moonlighting enzymes play?. American journal of human genetics. 2005, 76 (6): 911-924. 10.1086/430799PubMedCentralCrossRefPubMed
47.
go back to reference Tian W, Arakaki AK, Skolnick J: EFICAz: a comprehensive approach for accurate genome-scale enzyme function inference. Nucleic acids research. 2004, 32 (21): 6226-6239. 10.1093/nar/gkh956PubMedCentralCrossRefPubMed Tian W, Arakaki AK, Skolnick J: EFICAz: a comprehensive approach for accurate genome-scale enzyme function inference. Nucleic acids research. 2004, 32 (21): 6226-6239. 10.1093/nar/gkh956PubMedCentralCrossRefPubMed
48.
go back to reference Arakaki AK, Tian W, Skolnick J: High precision multi-genome scale reannotation of enzyme function by EFICAz. BMC genomics. 2006, 7: 315- 10.1186/1471-2164-7-315PubMedCentralCrossRefPubMed Arakaki AK, Tian W, Skolnick J: High precision multi-genome scale reannotation of enzyme function by EFICAz. BMC genomics. 2006, 7: 315- 10.1186/1471-2164-7-315PubMedCentralCrossRefPubMed
50.
go back to reference Horne AB, Hodgman TC, Spence HD, Dalby AR: Constructing an enzyme-centric view of metabolism. Bioinformatics. 2004, 20 (13): 2050-2055. 10.1093/bioinformatics/bth199CrossRefPubMed Horne AB, Hodgman TC, Spence HD, Dalby AR: Constructing an enzyme-centric view of metabolism. Bioinformatics. 2004, 20 (13): 2050-2055. 10.1093/bioinformatics/bth199CrossRefPubMed
51.
Metadata
Title
Identification of metabolites with anticancer properties by computational metabolomics
Authors
Adrian K Arakaki
Roman Mezencev
Nathan J Bowen
Ying Huang
John F McDonald
Jeffrey Skolnick
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-57

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine